Ichiro Abe. Efficacy and Safety of Low-Dose Ipragliflozin, a Selective Sodium Glucose Transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus. Int. J. of Allied Med. Sci. and Clin. Res. 2020, 4, 376-382.